Raquel Álvarez-García

Raquel Álvarez-García

Auto-generated profile, based on publicly available information

Raquel Álvarez-García

Hospital Rey Juan Carlos Móstoles

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2021 in Archives of Suicide Research
Verified
Journal Article
Closed access
CVConstanza Vera-Varela
Constanza Vera-Varela
PMPaulo César Manrique Mirón
Paulo César Manrique Mirón
MBMaria Luisa Barrigon
Maria Luisa Barrigon
RÁRaquel Álvarez-García
Raquel Álvarez-García
PPPablo Portillo
Pablo Portillo
EBEnrique Baca-Garcia
Enrique Baca-Garcia
Discrepancies between patient reports during clinical evaluations and self-reported suicide ideation are of vital importance. We study the agreement in passive suicidal ideation between reports mad...

26 January 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SBSofian Berrouiguet
Sofian Berrouiguet
MBMaria Luisa Barrigon
Maria Luisa Barrigon
SBSara A Brandt
Sara A Brandt
GNGeorge C Nitzburg
George C Nitzburg
SOSantiago Ovejero
Santiago Ovejero
EBEnrique Baca-Garcia
Enrique Baca-Garcia
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

26 August 2025 in European Psychiatry
Verified
Journal Article
Open access
PDF file
ICIsmaël Conejero
Ismaël Conejero
RGRaquel Alvarez García
Raquel Alvarez García
APAlejandro Porras-Segovia
Alejandro Porras-Segovia
ABAna María De Granda Beltrán
Ana María De Granda Beltrán
SLSergio Benavente López
Sergio Benavente López
MGMemind Group
Memind Group
Background: Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals. Methods: The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD. Standard esketamine protocol included an induction phase (4 weeks) and a maintenance phase (5 to 8 weeks). Subsequent treatment continuation was proposed. Clinical data and scores at the Clinical Global Impression scales were measured following each esketamine administration. Results: Sixty-five patients initiated the treatment, and 45 patients (69.2%) completed the standard protocol. The median number of esketamine administrations was 19. The mean age was 53.09 and 52.3% of the patients were females. Out of the whole sample, 36 (55%) of the patients achieved remission over the follow-up. Remission rates elevated to 67% in those who completed the standard protocol, and to 70% in those having received more than 19 esketamine administrations. Achieving remission over the follow-up was associated with the absence of dissociative symptoms, and with completing the standard esketamine protocol (OR = 0.229, p = 0.045; and OR = 4.538, p = 0.025, respectively). Receiving more than 19 esketamine administrations was associated with remission over the follow-up (OR = 6.513, p = 0.006). Conclusions: Our results suggest that extending the numbers of esketamine administration may increase the chances to obtain remission. Adverse effects did not impact the treatment course.

21 March 2025 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
JMJimena María Merayo-Cano
Jimena María Merayo-Cano
Alejandro Porras-SegoviaAlejandro Porras-Segovia
Alejandro Porras-Segovia
MTMaria Taracena-Cuerda
Maria Taracena-Cuerda
SGSofía Mesa García
Sofía Mesa García
IMInes Marti-Estevez
Ines Marti-Estevez
IPInmaculada Peñuelas-Calvo
Inmaculada Peñuelas-Calvo